Promoting Benzodiazepine Cessation Through an Electronically-delivered Patient Self-management Intervention

NCT04572750 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2026-01-23

Study results available
· View outcomes & findings →

Summary

Benzodiazepines (e.g., Ativan, Xanax) are widely prescribed medications that are used mainly to treat anxiety and sleeping difficulties. Long-term use of benzodiazepine carries risks of physical dependence, addiction, falls and other accidents, and problems in thinking/concentrating. Researchers in Canada developed a printed self-help packet that enabled many individuals to reduce or cease taking benzodiazepines on their own. This study is designed to tailor that packet to the Veteran population, convert it to an app that people can use on their laptop or smart phone, and test whether the app helps promote benzodiazepine prescribing.

Conditions

  • Taking Benzodiazepines for Any Reason for 3 Months
  • Benzodiazepine Dependence

Interventions

BEHAVIORAL

EMPOWER-ED

An electronic app that runs on a variety of platforms and provides education and tools designed to promote self-driven reduction of benzodiazepines.

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Keith N. Humphreys, PhD MA · VA Palo Alto Health Care System, Palo Alto, CA

  • Michael A Cucciare, PhD · Central Arkansas Veterans Healthcare System , Little Rock, AR

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2024-07-03
Completion
2024-07-03

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04572750 on ClinicalTrials.gov